Do analysts rate CPIX or NNVC?

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 455.56%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, PLYX or NNVC?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PLYX or NNVC more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A NanoViricides N/A -87.90% -78.69%

Does the media refer more to PLYX or NNVC?

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 2 articles in the media. NanoViricides' average media sentiment score of 0.51 beat Polaryx Therapeutics' score of 0.36 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PYPD or NNVC?

PolyPid is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PYPD or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% NanoViricides N/A -87.90% -78.69%

Which has better valuation and earnings, NNVC or CGTX?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A

Is NNVC or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Cognition Therapeutics N/A -50.17% -40.22%

Does the media favor NNVC or CGTX?

In the previous week, Cognition Therapeutics had 1 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Cognition Therapeutics and 2 mentions for NanoViricides. Cognition Therapeutics' average media sentiment score of 1.24 beat NanoViricides' score of 0.51 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRCA or NNVC?

In the previous week, NanoViricides had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for NanoViricides and 1 mentions for Verrica Pharmaceuticals. NanoViricides' average media sentiment score of 0.51 beat Verrica Pharmaceuticals' score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NanoViricides (NNVC) Competitors

$1.08 -0.04 (-3.57%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.06 (+5.65%)

As of 05:45 AM Eastern

Compare

NNVC vs. CPIX, PLYX, PYPD, CGTX, and VRCA

Should you buy NanoViricides stock or one of its competitors? NanoViricides's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), PolyPid (PYPD), Cognition Therapeutics (CGTX), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NanoViricides compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

NanoViricides has a consensus price target of $6.00, indicating a potential upside of 455.56%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts plainly believe NanoViricides is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cumberland Pharmaceuticals has higher revenue and earnings than NanoViricides. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.23	-$2.84M	-$0.71	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Cumberland Pharmaceuticals has a beta of 0.13, meaning that its stock price is 87% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NanoViricides had 2 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 2 mentions for NanoViricides and 0 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.75 beat NanoViricides' score of 0.51 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Positive
NanoViricides	Positive

NanoViricides has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
NanoViricides	N/A	-87.90%	-78.69%

Summary

NanoViricides beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does NanoViricides compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Polaryx Therapeutics presently has a consensus target price of $7.67, suggesting a potential upside of 279.54%. NanoViricides has a consensus target price of $6.00, suggesting a potential upside of 455.56%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
NanoViricides	N/A	-87.90%	-78.69%

10.3% of NanoViricides shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 2 articles in the media. NanoViricides' average media sentiment score of 0.51 beat Polaryx Therapeutics' score of 0.36 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NanoViricides beats Polaryx Therapeutics on 6 of the 11 factors compared between the two stocks.

How does NanoViricides compare to PolyPid?

PolyPid (NASDAQ:PYPD) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

26.5% of PolyPid shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NanoViricides had 2 more articles in the media than PolyPid. MarketBeat recorded 2 mentions for NanoViricides and 0 mentions for PolyPid. NanoViricides' average media sentiment score of 0.51 beat PolyPid's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Overall Sentiment
PolyPid	Neutral
NanoViricides	Positive

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 112.63%. NanoViricides has a consensus price target of $6.00, suggesting a potential upside of 455.56%. Given NanoViricides' stronger consensus rating and higher possible upside, analysts clearly believe NanoViricides is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

PolyPid is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

PolyPid has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

NanoViricides' return on equity of -87.90% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
NanoViricides	N/A	-87.90%	-78.69%

Summary

NanoViricides beats PolyPid on 10 of the 13 factors compared between the two stocks.

How does NanoViricides compare to Cognition Therapeutics?

NanoViricides (NYSE:NNVC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Cognition Therapeutics had 1 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Cognition Therapeutics and 2 mentions for NanoViricides. Cognition Therapeutics' average media sentiment score of 1.24 beat NanoViricides' score of 0.51 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cognition Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

NanoViricides currently has a consensus price target of $6.00, indicating a potential upside of 455.56%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 230.03%. Given NanoViricides' stronger consensus rating and higher probable upside, equities research analysts clearly believe NanoViricides is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics' return on equity of -50.17% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Cognition Therapeutics	N/A	-50.17%	-40.22%

Summary

Cognition Therapeutics beats NanoViricides on 9 of the 13 factors compared between the two stocks.

How does NanoViricides compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and NanoViricides (NYSE:NNVC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, NanoViricides had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for NanoViricides and 1 mentions for Verrica Pharmaceuticals. NanoViricides' average media sentiment score of 0.51 beat Verrica Pharmaceuticals' score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NanoViricides has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.54	-$17.89M	-$1.67	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Verrica Pharmaceuticals presently has a consensus price target of $12.67, indicating a potential upside of 140.81%. NanoViricides has a consensus price target of $6.00, indicating a potential upside of 455.56%. Given NanoViricides' stronger consensus rating and higher probable upside, analysts clearly believe NanoViricides is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

NanoViricides has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. NanoViricides' return on equity of -87.90% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
NanoViricides	N/A	-87.90%	-78.69%

Summary

NanoViricides beats Verrica Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$27.57M	$12.79B	$7.39B	$23.62B
Dividend Yield	N/A	2.59%	2.54%	3.73%
P/E Ratio	-1.50	782.38	270.75	29.07
Price / Sales	N/A	753.44	656.33	103.80
Price / Cash	N/A	90.26	77.07	33.53
Price / Book	1.64	11.02	10.88	4.79
Net Income	-$8.29M	$2.81B	$3.48B	$1.07B
7 Day Performance	-7.69%	-1.04%	-0.98%	-0.02%
1 Month Performance	-23.94%	4.13%	2.91%	-1.40%
1 Year Performance	-26.03%	6.37%	22.21%	12.56%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	2.051 of 5 stars	$1.08 -3.6%	$6.00 +455.6%	-25.0%	$27.57M	N/A	N/A	20	News Coverage
CPIX Cumberland Pharmaceuticals	0.7641 of 5 stars	$6.56 -1.9%	N/A	+100.0%	$100.24M	$44.52M	N/A	80
PLYX Polaryx Therapeutics	2.7987 of 5 stars	$1.98 -1.5%	$7.67 +287.2%	N/A	$100.19M	N/A	N/A	11
PYPD PolyPid	2.3598 of 5 stars	$5.33 +3.7%	$11.33 +112.6%	+54.0%	$98.09M	N/A	N/A	80	Positive News
CGTX Cognition Therapeutics	2.7787 of 5 stars	$1.01 -1.9%	$3.33 +230.0%	-57.9%	$97.95M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. CPIX, PLYX, PYPD, CGTX, and VRCA

How does NanoViricides compare to Cumberland Pharmaceuticals?

Summary

How does NanoViricides compare to Polaryx Therapeutics?

Summary

How does NanoViricides compare to PolyPid?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Summary

How does NanoViricides compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. CPIX, PLYX, PYPD, CGTX, and VRCA

How does NanoViricides compare to Cumberland Pharmaceuticals?

Do analysts rate CPIX or NNVC?

Which has better earnings and valuation, CPIX or NNVC?

Which has more risk and volatility, CPIX or NNVC?

Do institutionals & insiders have more ownership in CPIX or NNVC?

Does the media favor CPIX or NNVC?

Is CPIX or NNVC more profitable?

Summary

How does NanoViricides compare to Polaryx Therapeutics?

Which has higher valuation and earnings, PLYX or NNVC?

Do analysts recommend PLYX or NNVC?

Is PLYX or NNVC more profitable?

Do institutionals and insiders hold more shares of PLYX or NNVC?

Does the media refer more to PLYX or NNVC?

Summary

How does NanoViricides compare to PolyPid?

Do institutionals and insiders believe in PYPD or NNVC?

Does the media prefer PYPD or NNVC?

Do analysts prefer PYPD or NNVC?

Which has higher earnings and valuation, PYPD or NNVC?

Which has more volatility & risk, PYPD or NNVC?

Is PYPD or NNVC more profitable?

Summary

How does NanoViricides compare to Cognition Therapeutics?

Does the media favor NNVC or CGTX?

Do insiders & institutionals believe in NNVC or CGTX?

Which has better valuation and earnings, NNVC or CGTX?

Which has more risk and volatility, NNVC or CGTX?

Do analysts recommend NNVC or CGTX?

Is NNVC or CGTX more profitable?

Summary

How does NanoViricides compare to Verrica Pharmaceuticals?

Does the media prefer VRCA or NNVC?

Do insiders and institutionals have more ownership in VRCA or NNVC?

Which has stronger earnings & valuation, VRCA or NNVC?

Which has more risk and volatility, VRCA or NNVC?

Do analysts rate VRCA or NNVC?

Is VRCA or NNVC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools